<DOC>
	<DOC>NCT02504268</DOC>
	<brief_summary>The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.</brief_summary>
	<brief_title>Effects of Abatacept in Patients With Early Rheumatoid Arthritis</brief_title>
	<detailed_description>Subcutaneous (SC)</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Rheumatoid arthritis (RA) diagnosis less than 6 months CRP &gt; 3 mg/L or Erythrocyte Sedimentation Rate (ESR) â‰¥ 28 mm/h At least 3 swollen and 3 tender joints Anticitrullinated protein antibodies (ACPA) positive At risk for tuberculosis Have acute infection Have chronic or recurrent bacterial or serious latent viral infection History of malignancies in the last 5 years except squamous skin, basal skin or cervical carcinoma Previous treatment with any conventional or biologic Diseasemodifying anti rheumatic drugs (DMARD)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>